AVITA Medical CFO David McIntyre to Depart Effective June 30

AVITA Medical, Inc. reported that Chief Financial Officer David McIntyre will depart the company effective June 30, 2026.

The filing, submitted to the SEC on June 4 under Items 5.02 and 5.07, lists McIntyre’s separation with no cause or disagreement cited. Item 5.02 requires companies to disclose departures of principal officers and the effective date; the document supplies both.

McIntyre has served as CFO of the regenerative-medicine company, which markets FDA-approved products for burn and wound care. His exit removes the principal financial officer responsible for SEC reporting, internal controls, and capital-market communications. The company has not yet named a successor or interim replacement in the filing.

Operationally, AVITA must either appoint a new CFO or designate an interim officer by June 30 to maintain uninterrupted financial oversight and timely Exchange Act filings. Under SEC rules, a permanent or interim appointment typically prompts a subsequent Form 8-K within four business days.

The company’s next quarterly report on Form 10-Q, covering the period ending June 30, will also require certification by the principal financial officer or acting equivalent.

Downstream, the transition activates standard post-employment obligations such as severance, equity vesting determinations, and potential Form 4 filings for any final stock transactions. If no successor is disclosed promptly, AVITA risks delayed compliance with Regulation S-K Item 601(b)(10) exhibits or other officer-related disclosures required in its upcoming proxy or 10-K.

Investors and counterparties will look for the successor’s identity, background, and any compensation arrangements, which must be reported in a follow-on 8-K.

This marks the second executive-level change AVITA has reported via Item 5.02 in the past 24 months. The June 4 filing also covered routine matters submitted to a shareholder vote under Item 5.07, but those results were not tied to the CFO transition.

Primary sources: SEC Form 8-K filed June 4, 2026 (Accession No. 0001762303-26-000003).